Pharmena S.A. (WSE:PHR)
Poland
· Delayed Price · Currency is PLN 3.460
-0.060 (-1.70%)
Mar 9, 2026, 12:10 PM CET
Pharmena Company Description
Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally.
It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications.
Pharmena S.A. was founded in 2002 and is based in Lódz, Poland.
Pharmena S.A.
| Country | Poland |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Konrad Palka |
Contact Details
Address: Gdanska 47/49 Lódz, 90-729 Poland | |
| Phone | 48 42 280 77 07 |
| Website | pharmena.eu |
Stock Details
| Ticker Symbol | PHR |
| Exchange | Warsaw Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| ISIN Number | PLPHRMN00011 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Konrad Palka | President of Management Board, Chief Executive Officer and President |
| Marzena Wieczorkowska | Vice President of the Management Board and VP of Research and Development |